Ng recombinant vaccinia: implications for vaccine improvement. J Exp Med. 1992; 176:169?76. [PubMed: 1377222] 10. Burrows SR, Sculley TB, Misko IS, Schmidt C, Moss DJ. An Epstein-Barr virus- specific cytotoxic T cell epitope in EBV nuclear antigen three (EBNA three). J Exp Med. 1990; 171:345?49. [PubMed: 1688611] 11? Elliott SL, Suhrbier A, Miles JJ, Lawrence G, Pye SJ, Le TT, Rosenstengel A, Nguyen T, Allworth A, Burrows SR, et al. Phase I trial of a CD8+ T-cell peptide epitope-based vaccine for infectious mononucleosis. J Virol. 2008; 82:1448?457. A feasibility trial that demonstrated safety and immunogenicity of an EBV CD8+ T-cell peptide vaccine. When not practical for common use because of HLA restriction, it could possibly be studied in subjects whose HLA is properly characterized, including pretransplant candidates. [PubMed: 18032491] 12 . Hui EP, Taylor GS, Jia H, Ma BB, Chan SL, Ho R, Wong WL, Wilson S, Johnson BF, Edwards C, et al. Phase I trial of recombinant modified vaccinia Ankara encoding Epstein-Barr viral tumor antigens in nasopharyngeal carcinoma sufferers. Cancer Res. 2013; 73:1676?688. A completely made trial whose hypothesis is the fact that enhanced recognition of tumor cells through their expression of EBNA antigens EBNA-1 and LMP-2 might be therapeutic. Security, immunogenicity, and a dose-response impact were demonstrated. [PubMed: 23348421] 13. Balfour HH Jr. Epstein-Barr virus vaccine for the Epoxide Hydrolase custom synthesis prevention of infectious mononucleosis–and what else? J Infect Dis. 2007; 196:1724?726. [PubMed: 18190249]NIH-PA Author Manuscript NIH-PA Author Manuscript NIH-PA Author ManuscriptCurr Opin Virol. Author manuscript; offered in PMC 2015 June 01.BalfourPage14. Nemerow GR, Mold C, Schwend VK, Tollefson V, Cooper NR. Identification of gp350 because the viral glycoprotein mediating attachment of Epstein-Barr virus (EBV) for the EBV/C3d receptor of B cells: sequence homology of gp350 and C3 complement fragment C3d. J Virol. 1987; 61:1416?1420. [PubMed: 3033269] 15. Moss DJ, Pope JH. Assay of your infectivity of Epstein-Barr virus by transformation of human leucocytes in vitro. J Gen Virol. 1972; 17:233?36. [PubMed: 4344316] 16. Sashihara J, Burbelo PD, Savoldo B, Pierson TC, Cohen JI. Human antibody titers to Epstein-Barr Virus (EBV) gp350 correlate with neutralization of infectivity better than antibody titers to EBV gp42 employing a fast flow cytometry-based EBV neutralization assay. Virology. 2009; 391:249?56. [PubMed: 19584018] 17. Moghaddam A, Rosenzweig M, Lee-Parritz D, Annis B, Johnson RP, Wang F. An animal model for acute and persistent Epstein-Barr virus infection. Science. 1997; 276:2030?033. [PubMed: 9197263] 18? Sashihara J, Hoshino Y, Bowman JJ, Krogmann T, Burbelo PD, Coffield VM, Kamrud K, Cohen JI. PAK3 manufacturer Soluble rhesus lymphocryptovirus gp350 protects against infection and reduces viral loads in animals that become infected with virus after challenge. PLoS Pathog. 2011; 7:e1002308. A crucial study in which rhesus macques have been protected from an EBV challenge infection following receiving gp350 vaccine. [PubMed: 22028652] 19? Balfour HH Jr, Odumade OA, Schmeling DO, Mullan BD, Ed JA, Knight JA, Vezina HE, Thomas W, Hogquist KA. Behavioral, virologic, and immunologic elements linked with acquisition and severity of principal Epstein-Barr virus infection in university students. J Infect Dis. 2013; 207:80?eight. A potential study demonstrating the important disease burden of principal EBV infection in EBV-na e college freshmen. Such students are best subjects.
